The nano delivery systems and applications of mRNA

Li, Mingyuan; Li, Yuan; Li, Shiqin; Jia, Lin; Wang, Haomeng; Li, Meng; Deng, Jie; Zhu, Ali; Ma, Liqiao; Li, Weihong; Yu, Peng; Zhu, Tao

doi:10.1016/j.ejmech.2021.113910

Cited by 72 publications

(70 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The capsulation of mRNA with LNP can effectively transfer mRNA into cells and induce a strong immune response; thus is widely used in most mRNA vaccines, including BNT162b2 and mRNA-1273. 71 , 72 In addition, other delivery systems like lipopolyplexes, polymer nanoparticles, cationic polypeptides, and polysaccharide particles also provide unlimited possibilities for the improvement of mRNA vaccine . 72 , 73 …”

Section: Existing Vaccine Platforms For Covid-19 Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 vaccine development: milestones, lessons and prospects

Wang²,

Tian

et al. 2022

Sig Transduct Target Ther

233

211

View full text Add to dashboard Cite

With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.

show abstract

Section: Existing Vaccine Platforms For Covid-19 Vaccinesmentioning

confidence: 99%

“… 71 , 72 In addition, other delivery systems like lipopolyplexes, polymer nanoparticles, cationic polypeptides, and polysaccharide particles also provide unlimited possibilities for the improvement of mRNA vaccine . 72 , 73 …”

Section: Existing Vaccine Platforms For Covid-19 Vaccinesmentioning

confidence: 99%

COVID-19 vaccine development: milestones, lessons and prospects

Wang²,

Tian

et al. 2022

Sig Transduct Target Ther

233

211

View full text Add to dashboard Cite

show abstract

“…TNAs can also be employed in formulations for the treatment and prevention of cardiovascular diseases [37,38]. Clinical trials have investigated ASOs for lowering low-density lipoprotein cholesterol (LDL-C) [39], lowering transthyretin (TTR) blood levels [40][41][42], reducing atrial fibrillation burden [43], reducing serum lipoprotein (a) levels [44], and preventing neovascular glaucoma [45].…”

Section: Lipid-based Delivery Systemsmentioning

confidence: 99%

“…Clinical trials demonstrated the efficacy of LNP-mRNA formulations and an acceptable safety profile, leading to their approval for mass immunization [58,59]. COVID-19 vaccines are the most known current examples that make use of LNPs encapsulated with TNA, but this approach can be used for other infectious diseases as well [37,[61][62][63][64][65][66][67]. TNA-LNP formulations have been evaluated against Zika virus [68], influenza [69,70], cytomegalovirus [71,72], chikungunya virus [73], hepatitis B [74][75][76], hepatitis C [77][78][79], human immunodeficiency virus (HIV) [80,81], and genital herpes [82].…”

Section: Lipid-based Delivery Systemsmentioning

confidence: 99%

“…The development of nonviral platforms for prenatal TNA delivery has recently emerged among the scientific research hot topics as a strategy to treat diseases before the onset of irreversible pathology and a non-invasive alternative to difficult-to-perform surgeries. What is more, the small size of a fetus compared to a postnatal recipient is a key factor for maximizing the delivery vector titer per weight of the recipient, thus, facilitating gene transduction [37,83]. In this regard, Riley et al [84] have recently developed a library of ionizable LNPs for in utero mRNA delivery to mouse fetuses.…”

Section: Lipid-based Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery

2021

View full text Add to dashboard Cite

Nucleic acids represent a promising lead for engineering the immune system. However, naked DNA, mRNA, siRNA, and other nucleic acids are prone to enzymatic degradation and face challenges crossing the cell membrane. Therefore, increasing research has been recently focused on developing novel delivery systems that are able to overcome these drawbacks. Particular attention has been drawn to designing lipid and polymer-based nanoparticles that protect nucleic acids and ensure their targeted delivery, controlled release, and enhanced cellular uptake. In this respect, this review aims to present the recent advances in the field, highlighting the possibility of using these nanosystems for therapeutic and prophylactic purposes towards combatting a broad range of infectious, chronic, and genetic disorders.

show abstract

Novel Ionizable Lipid Nanoparticles for SARS‐CoV‐2 Omicron mRNA Delivery

Long

Zhang³

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

mRNA-based therapy has emerged as the most promising nucleic acid therapy in the fight against COVID-19. However, a safe and efficacious systemic delivery remains a challenge for mRNA therapy. Lipid nanoparticles (LNPs) are currently widely used in mRNA delivery vehicles. Here, a series of ionizable LNPs is rationally designed. YK009-LNP is an optimal delivery platform to carry mRNA. YK009-LNP exhibits higher mRNA delivery efficiency, a more favorable biodistribution pattern, and better safety than the approved MC3-LNP. In addition, mRNA encoding severe acute respiratory syndrome coronavirus 2 Omicron receptor binding domain protein is synthesized and intramuscular administration of mice with YK009-LNP-Omicron mRNA induces a robust immune response and immune protective effect. A novel mRNA delivery vehicle with more powerful delivery efficiency and better safety than the approved LNPs is provided here.

show abstract

The nano delivery systems and applications of mRNA

Cited by 72 publications

References 114 publications

COVID-19 vaccine development: milestones, lessons and prospects

COVID-19 vaccine development: milestones, lessons and prospects

New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery

Novel Ionizable Lipid Nanoparticles for SARS‐CoV‐2 Omicron mRNA Delivery

Contact Info

Product

Resources

About